NIAID Initiates Trial of Experimental Avian Flu Vaccine
Fast-track recruitment has begun for a trial to investigate the safety of a vaccine against H5N1 avian influenza, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), announced today. . .. “While there have been relatively few cases worldwide of H5N1 avian influenza infection in humans, the public health community is concerned that t...NIAID begins clinical trial of West Nile virus vaccine
A small trial testing the safety of an experimental vaccine targeting West Nile virus (WNV) opened today at the National Institutes of Health's (NIH) Clinical Center in Bethesda, MD. The vaccine, which will be tested first in 15 healthy adult volunteers, was developed for human clinical studies by researchers at the National Institute of Allergy and Infectious Diseases' (NIAID) Vaccine Research C...New NIAID grants strengthen national biodefense and emerging infectious diseases research network
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced four-year grants totaling approximately $80 million for two new Regional Centers of Excellence for Biodefense and Emerging Infectious Diseases Research (RCE). The grants to the University of California, Irvine, and Colorado State University (Fort Collins) mark the completi...NIAID researchers show how promising TB drug works
Scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have determined how a promising drug candidate attacks the bacterium that causes tuberculosis (TB). Published online this week in Proceedings of the National Academy of Sciences, the finding may help scientists optimize the drug candidate, PA-824, which targets Mycobacteri...NIAID DNA vaccine for H5N1 avian influenza enters human trial
The first human trial of a DNA vaccine designed to prevent H5N1 avian influenza infection began on December 21, 2006, when the vaccine was administered to the first volunteer at the National Institutes of Health (NIH) Clinical Center in Bethesda, MD. Scientists from the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), one of the NIH Institutes, d...NIAID expands capability for influenza research and surveillance
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), today announced it is awarding $23 million per year for seven years to establish six Centers of Excellence for Influenza Research and Surveillance. Collectively, the centers will expand NIAID’s influenza surveillance program internationally and in the United States, and will bolster...